BioXcel Therapeutics will host a Key Opinion Leader Day focused on its lead immuno-oncology program BXCL701 for the investment community on Tuesday, February 21, 2023 from 1:00 to 3:00 p.m. ET. Vimal Mehta, Ph.D., CEO, and Vincent O’Neill, M.D., Chief R&D Officer, OnkosXcel Therapeutics, a wholly owned subsidiary of BioXcel Therapeutics, Inc., will be joined by a panel of leading oncology experts to review top-line Phase 2 data results being presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, and the development path and future opportunities for BXCL701, which is currently being developed for the potential treatment of small cell neuroendocrine prostate cancer, an aggressive variant of prostate cancer.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BTAI:
- BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer
- BioXcel Therapeutics price target raised to $38 from $24 at Mizuho
- BioXcel Therapeutics announces results from Phase 2 trial of BXCL701
- BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer
- BioXcel Therapeutics price target lowered to $73 from $85 at H.C. Wainwright
